SILO - CONSENSUS CO - Silo Pharma, Inc.

Silo Pharma, Inc. (SILO) is attracting leading neurobiologists through its work with psychedelics, utilizing RSUs and generous research funding. This price chart confirms market expectations, where the indicator stands at 150.61. The company is developing safe treatments for Alzheimer's and pain that eliminate hallucinations. Due to its ethical approach and breakthroughs in neurology, the brand inspires deep trust among physicians and steady interest from shareholders.

For Silo Pharma, Inc. (SILO), which is developing innovative therapies for dementia and PTSD through university partnerships, this indicator reflects market expectations regarding the value of future intellectual assets. The arithmetic mean of expert target prices, shown on this analyst average target price chart, allows for the differentiation of temporary volatility from a systemic revision of business value, thereby determining the fair growth potential of the shares.